top of page

EC approves Daklinza in three new HCV patient populations

The European Commission has approved Bristol-Myers Squibb’s Daklinza (daclatasvir) for the treatment of chronic hepatitis C (HCV) in three new patient populations.


Click on this link for more information.

source: http://www.europeanpharmaceuticalreview.com/38353/news/industry-news/ec-approves-daklinza-in-three-new-hcv-patient-populations/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page